HJB - Your Trusted Biologics CDMO Partner
HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB
Dec, 2024
HANGZHOU, China, December 4, 2024 – HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that the Center for Drug Evaluation of China’s National Medical Products Administration has granted clearance of the company’s Investigational New Drug (IND) application to begin a clinical trial of HF50 in patients with advanced solid tumor cancers.
HJB extends warm congratulations and is honored to have provided services such as cell line development, master cell bank establishment, and 25L wave cell culture in GMP and R&D laboratory environments for this project.
BD@hjbbio.com
